Germany Daily Briefing

A US court ruling applying federal preemption to glyphosate (Roundup) cancer warning claims sent Bayer's shares surging approximately 20% intraday — the most significant single-day move for a DAX heavyweight in years. If the preemption argument holds through appeal, Bayer's multi-billion-dollar litigation tail shrinks materially, and the market is pricing that scenario aggressively today. FAZ notes analysts believe there is further upside; DW's analysis covers the legal history of why so many Roundup lawsuits exist. The key caveat: this is one ruling, not Supreme Court precedent — the appeal risk is real and the position is speculative until the legal chain clarifies.

FAZ's Börsenwoche analysis reports markets are calming after the Iran-US Hormuz framework with oil prices easing and first tankers moving again through the strait — but 'vorerst' (for now) is doing a lot of work in that headline. For Germany specifically, cheaper energy is a positive for energy-intensive industrial and chemical production, and the Energiewende transition benefits from normalized LNG imports. However, FAZ notes market nervousness persists: the framework is fragile, and both sides are trading ceasefire-violation accusations. DAX industrials and chemicals (BASF adjacent) will re-rate positively if Hormuz normalization holds through summer.

Bremen-based satellite manufacturer OHB sold more shares to investors than initially planned in its IPO, targeting the MDAX — and FAZ notes interest was substantial from institutional investors positioning on the European defense-space convergence theme. OHB's satellite contracts are government-dominated (ESA + Bundeswehr adjacent), which gives it revenue visibility that commercial peers lack. The SpaceX index inclusion happening globally this week creates a sentiment halo for space-sector equity broadly; OHB's MDAX debut timing is favorable.